Clinical characteristics of patients in the increased-, stable-, and decreased-RPR groups. by Kazuhiko Ikeuchi (9234268)

Subjects:

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

“…Treatment with GSK343 significantly decreased tumorsphere formation by both the COA3 (A) and COA6 (B) cells, representing a decrease in stem cell-like phenotype. …”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

* months from treatment initiation. by Kazuhiko Ikeuchi (9234268)

Subjects:

Association between the slope of the ratio of the post-treatment RPR titer compared to the baseline titer and other characteristics using linear regression analysis. by Kazuhiko Ikeuchi (9234268)

Subjects:

Temporal changes in the RPR titer from before to after treatment. by Kazuhiko Ikeuchi (9234268)

Subjects:

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

Subjects:

CCR2 depletion decreases lipid accumulation in the liver and WAT. by Seung Joo Lee (1766020)

“…<p>(a) To analyze lipid accumulation in tissues, H&E staining was performed. Increased lipid droplets and fat size in HFD WT were decreased in HFD KO. …”

Presence of <i>Klf4</i> promoter elements decreases the effects of enhancer E2 in reporter assays. by Jack B. Waite (19762178)

E₅₀ values. by Junxia Zhou (14381598)

Conditions that ablate cytonemes decrease signaling, reduce myoblast and tumor growth. by Sol Fereres (664350)

E₅₀ values of angle. by Junxia Zhou (14381598)

Curve fitting of E₅₀. by Junxia Zhou (14381598)

Fitting curves of E₅₀. by Junxia Zhou (14381598)

E₅₀ values of size. by Junxia Zhou (14381598)

E₅₀ fluctuation coefficient. by Junxia Zhou (14381598)

Fitting relationship of E₅₀. by Junxia Zhou (14381598)

Fitting curve of E₅₀. by Junxia Zhou (14381598)

Proteasomal activity decreases with ApoE4 expression. by Nathan R. Zuniga (20422428)